GIMBHI‘s Q&A with Heading Health’s CEO, Simon Tankel

Simon is a British born entrepreneur, who immigrated to the US in 2020 inspired to partner with the US healthcare system to bring mass access to psychedelic therapies. Prior ventures are Sum Energy (Israeli power generation, exited to ICP) and Iuvo (insurance covered medical cannabis).


What does Heading Health do?

Heading Health is an interventional psychiatry provider group, our go to market is ketamine/esketamine therapy for treatment resistant depression, where we are in Texas with 6 locations to date. We've paid particular attention in driving adherence, outcomes and engagement through several specific levers such as in network payor coverage, intelligent design decisions and a dedication to providing unreasonable hospitality to a depressed patient population which is particularly sensitive.


What does the future of interventional psychiatry look like?

The future of interventional psychiatry is phenotyping individual patient's pathways in order to drive payor value and rapid acting patient success for underserved populations. In the medium term, it's much more about delivering access to the most effective tools in the toolbox for providers by opening more locations and adding more modalities such as neuromodulation, changing providers behavior through culture and incentives to prioritize rapid acting responses and lastly understanding the behavioral nudges to both attract and engage patients at scale. I'm particularly excited by the work to both shorten some of the psychedelic treatments as well as to drive outcomes remotely through bioelectronics (remote TMS inserted into the brain).

Subscribe to news and reports about mental health startups & mental health investors at gimbhi.substack.com